[ad_1]
SILVER SPRING, Md. – The United States Food and Drug Administration alerts health care professionals and patients of a voluntary recall of several drugs containing the active ingredient valsartan, used to treat bad cancer. # 39; arterial hypertension and heart failure
This recall is due to an impurity, N-nitrosodimethylamine (NDMA), present in the recalled products. However, not all products containing valsartan are recalled.
NDMA is clbadified as possibly carcinogenic to humans (a substance which can cause cancer) according to the results of laboratory tests. The presence of NDMA was unexpected and would be related to changes in the way the active substance was manufactured.
The FDA review is underway and included the study of NDMA levels in the recalled products, evaluating the possible effect on the patients who took them and what measures can be taken to reduce or eliminate the impurity of future batches produced by the company.
"The FDA is committed to maintaining our standard of excellence in safety and effectiveness." When we identify failures in the quality of drugs and manufacturing problems that may create risks for patients, we are able to determine the quality of drugs and the safety of their manufacture, "says Scott Gottlieb, MD, FDA.We are committed to taking prompt action to alert the public and help facilitate the removal of the products from the market and I am also working hard to ensure that the therapeutic needs of patients are met in the United States with an adequate supply of unaffected drugs. "
Information for Patients and Health Professionals [19659007] Valsartan is used in drug therapy patients taking medications containing valsartan recalled should continue to take their medications until they have a substitute.
Recalled Products "We have carefully evaluated drugs containing valsartan sold in the United States, and we have found that valsartan sold by these specific companies does not meet our safety and that is why we asked these companies to take immediate action to protect patients, "said Janet Woodbad, MD, director of the FDA Cent for Drug Evaluation and Research.
[ad_2]
Source link